Cargando…

Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma

Mostrar otras versiones (1)

BACKGROUND: Patients with recurrent glioblastoma have a poor outcome. Data from the phase III registration trial comparing tumour-treating alternating electric fields (TTFields) vs chemotherapy provided a unique opportunity to study dexamethasone effects on patient outcome unencumbered by the confou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, E T, Lok, E, Gautam, S, Swanson, K D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506397/ https://www.ncbi.nlm.nih.gov/pubmed/26125449 http://dx.doi.org/10.1038/bjc.2015.238

Ejemplares similares

Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma
por: Wong, E T, et al.
Publicado: (2015)

Response to: Comment on ‘Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma'
por: Wong, Eric T, et al.
Publicado: (2015)

Comment on ‘Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma'
por: Ellsworth, Susannah, et al.
Publicado: (2015)

H1/pHGFK1 nanoparticles exert anti-tumoural and radiosensitising effects by inhibition of MET in glioblastoma
por: Zhang, Wenyan, et al.
Publicado: (2018)

A mathematical modelling tool for predicting survival of individual patients following resection of glioblastoma: a proof of principle
por: Swanson, K R, et al.
Publicado: (2008)

Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms
por: Gujar, S A, et al.
Publicado: (2014)

A pilot clinical study of Δ(9)-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme
por: Guzmán, M, et al.
Publicado: (2006)

hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines
por: Masi, A, et al.
Publicado: (2005)

Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact
por: Alì, G, et al.
Publicado: (2009)

Combination of temozolomide with immunocytokine F16–IL2 for the treatment of glioblastoma
por: Pedretti, M, et al.
Publicado: (2010)

RNA interference as a key to knockdown overexpressed cyclooxygenase-2 gene in tumour cells
por: Strillacci, A, et al.
Publicado: (2006)

Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma
por: Karakhanova, S, et al.
Publicado: (2015)

Heat-shock protein 70-dependent dendritic cell activation by 5-aminolevulinic acid-mediated photodynamic treatment of human glioblastoma spheroids in vitro
por: Etminan, N, et al.
Publicado: (2011)

LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model
por: Fuh, B, et al.
Publicado: (2009)

Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant
por: Zakaria, Z, et al.
Publicado: (2016)

Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models
por: Jarzabek, M A, et al.
Publicado: (2014)

IGF-IR: a new prognostic biomarker for human glioblastoma
por: Maris, C, et al.
Publicado: (2015)

Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells
por: Strillacci, A, et al.
Publicado: (2010)

TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells
por: Cantarella, G, et al.
Publicado: (2006)

Regulation of hypoxia-induced autophagy in glioblastoma involves ATG9A
por: Abdul Rahim, Siti Aminah, et al.
Publicado: (2017)

BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML
por: Lin, W-H, et al.
Publicado: (2012)

Telomerase reverse transcriptase inhibition stimulates cyclooxygenase 2 expression in cancer cells and synergizes with celecoxib to exert anti-cancer effects
por: Liu, T, et al.
Publicado: (2013)

Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo
por: Gibert, B, et al.
Publicado: (2012)

Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells
por: D'Amato, C, et al.
Publicado: (2014)

Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts
por: Vlahovic, G, et al.
Publicado: (2007)

Effects of opioids on immunologic parameters that are relevant to anti-tumour immune potential in patients with cancer: a systematic literature review
por: Boland, J W, et al.
Publicado: (2014)

Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival
por: Robinson, C G, et al.
Publicado: (2010)

KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma
por: White, N M A, et al.
Publicado: (2009)

Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients
por: Wilbaux, M, et al.
Publicado: (2014)

Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells
por: Liu, P, et al.
Publicado: (2012)

Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin
por: Piccirillo, S G M, et al.
Publicado: (2012)

The role of superoxide anions in the development of distant tumour recurrence
por: ten Kate, M, et al.
Publicado: (2006)

Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours
por: Hussein, D, et al.
Publicado: (2009)

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
por: Martinelli, M, et al.
Publicado: (2007)

(212)Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint
por: Yong, K J, et al.
Publicado: (2013)

Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling
por: Han, Sheng, et al.
Publicado: (2017)

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
por: Parakh, Sagun, et al.
Publicado: (2017)

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer
por: Fujita, T, et al.
Publicado: (2006)

TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy
por: Pirovano, Giacomo, et al.
Publicado: (2017)

Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer
por: Mochiki, E, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_gaiad52il18jctbonnoogbqjjc